Enise Sezer 1637916| Formulariumadvies prostaatcarcinoom, atriumfibrilleren, |GFA-2.FC3-21| 12-04-2024
Formulariumadvies
VERGELIJKINGSMATRIX INDICATIES
ONCOLOGIE PROSTAATCARCINOOM (ENZALUTAMIDE – ABIRATERON)
INTERNE GENEESKUNDE ATRIUMFIBRILLEREN (DAPIGATRAN – RIVAROXABAN)
DATUM: 12 APRIL 2024
CURSUSCODE: GFA-2.FC3-21
DOCENT: RUTH TENNEKES
NAAM STUDENT: ENISE SEZER
STUDENTNUMMER: 1637916
,Inhoudsopgave
Formulariumadvies prostaatcarcinoom.......................................................................................................... 3
Enzalutamide – abirateron...................................................................................................................................3
Inleiding...........................................................................................................................................................3
Prostaatcarcinoom...............................................................................................................................................4
Medicatie bij prostaatcarcinoom.........................................................................................................................4
Effectiviteit...........................................................................................................................................................4
Veiligheid..............................................................................................................................................................5
Tolerantie.............................................................................................................................................................5
Gebruikersgemak.................................................................................................................................................5
Kosten...................................................................................................................................................................6
Conclusie...............................................................................................................................................................6
Vergelijkinsgmatrix prostaatcarcinoom, enzalutamide – abiraterone..............................................................8
Bronnenlijst Vergelijkinsgmatrix prostaatcarcinoom, enzalutamide – abiraterone........................................12
Formulariumadvies atriumfibrilleren............................................................................................................ 13
dabigatran – rivaroxaban..................................................................................................................................13
Inleiding.........................................................................................................................................................14
Medicatie bij atriumfibrilleren...........................................................................................................................14
Effectiviteit.........................................................................................................................................................14
Veiligheid............................................................................................................................................................15
Tolerantie...........................................................................................................................................................15
Gebruikersgemak...............................................................................................................................................15
Ervaring..............................................................................................................................................................16
Kosten.................................................................................................................................................................16
Conclusie............................................................................................................................................................16
Vergelijkinsgmatrix Atriumfibrilleren, dabigatran – rivaroxaban...................................................................15
Bronnenlijst Vergelijkinsgmatrix dabigatran – rivaroxavan...........................................................................19
Formulariumadvies prostaatcarcinoom.......................................................................................................... 3
Enzalutamide – abirateron..................................................................................................................................3
Inleiding...........................................................................................................................................................3
Prostaatcarcinoom...............................................................................................................................................3
Medicatie bij prostaatcarcinoom.........................................................................................................................3
Effectiviteit...........................................................................................................................................................3
2
, Enise Sezer 1637916| Formulariumadvies prostaatcarcinoom, atriumfibrilleren, |GFA-2.FC3-21| 12-04-2024
Veiligheid..............................................................................................................................................................4
Tolerantie.............................................................................................................................................................4
Gebruikersgemak.................................................................................................................................................4
Kosten...................................................................................................................................................................5
Conclusie..............................................................................................................................................................5
Vergelijkinsgmatrix prostaatcarcinoom, enzalutamide – abiraterone.............................................................6
Bronnenlijst Vergelijkinsgmatrix prostaatcarcinoom, enzalutamide – abiraterone........................................10
Formulariumadvies atriumfibrilleren........................................................................................................... 12
dabigatran – rivaroxaban..................................................................................................................................12
Inleiding.........................................................................................................................................................12
Medicatie bij atriumfibrilleren...........................................................................................................................12
Effectiviteit.........................................................................................................................................................12
Veiligheid............................................................................................................................................................13
Tolerantie...........................................................................................................................................................13
Gebruikersgemak...............................................................................................................................................13
Ervaring..............................................................................................................................................................14
Kosten................................................................................................................................................................14
Conclusie............................................................................................................................................................14
Vergelijkinsgmatrix Atriumfibrilleren, dabigatran – rivaroxaban...................................................................15
Bronnenlijst Vergelijkinsgmatrix dabigatran – rivaroxavan...........................................................................19
Formulariumadvies prostaatcarcinoom
Enzalutamide – abirateron
Inleiding
Het ziekenhuis heeft op verzoek van de formulariumcommissie twee geneesmiddelen,
enzalutamide en abiraterone, geëvalueerd voor de behandeling van prostaatkanker. Deze
evaluatie omvatte een vergelijking op basis van verschillende criteria, waaronder effectiviteit,
veiligheid, tolerantie, gebruikersgemak, ervaring en kosten.
3
Formulariumadvies
VERGELIJKINGSMATRIX INDICATIES
ONCOLOGIE PROSTAATCARCINOOM (ENZALUTAMIDE – ABIRATERON)
INTERNE GENEESKUNDE ATRIUMFIBRILLEREN (DAPIGATRAN – RIVAROXABAN)
DATUM: 12 APRIL 2024
CURSUSCODE: GFA-2.FC3-21
DOCENT: RUTH TENNEKES
NAAM STUDENT: ENISE SEZER
STUDENTNUMMER: 1637916
,Inhoudsopgave
Formulariumadvies prostaatcarcinoom.......................................................................................................... 3
Enzalutamide – abirateron...................................................................................................................................3
Inleiding...........................................................................................................................................................3
Prostaatcarcinoom...............................................................................................................................................4
Medicatie bij prostaatcarcinoom.........................................................................................................................4
Effectiviteit...........................................................................................................................................................4
Veiligheid..............................................................................................................................................................5
Tolerantie.............................................................................................................................................................5
Gebruikersgemak.................................................................................................................................................5
Kosten...................................................................................................................................................................6
Conclusie...............................................................................................................................................................6
Vergelijkinsgmatrix prostaatcarcinoom, enzalutamide – abiraterone..............................................................8
Bronnenlijst Vergelijkinsgmatrix prostaatcarcinoom, enzalutamide – abiraterone........................................12
Formulariumadvies atriumfibrilleren............................................................................................................ 13
dabigatran – rivaroxaban..................................................................................................................................13
Inleiding.........................................................................................................................................................14
Medicatie bij atriumfibrilleren...........................................................................................................................14
Effectiviteit.........................................................................................................................................................14
Veiligheid............................................................................................................................................................15
Tolerantie...........................................................................................................................................................15
Gebruikersgemak...............................................................................................................................................15
Ervaring..............................................................................................................................................................16
Kosten.................................................................................................................................................................16
Conclusie............................................................................................................................................................16
Vergelijkinsgmatrix Atriumfibrilleren, dabigatran – rivaroxaban...................................................................15
Bronnenlijst Vergelijkinsgmatrix dabigatran – rivaroxavan...........................................................................19
Formulariumadvies prostaatcarcinoom.......................................................................................................... 3
Enzalutamide – abirateron..................................................................................................................................3
Inleiding...........................................................................................................................................................3
Prostaatcarcinoom...............................................................................................................................................3
Medicatie bij prostaatcarcinoom.........................................................................................................................3
Effectiviteit...........................................................................................................................................................3
2
, Enise Sezer 1637916| Formulariumadvies prostaatcarcinoom, atriumfibrilleren, |GFA-2.FC3-21| 12-04-2024
Veiligheid..............................................................................................................................................................4
Tolerantie.............................................................................................................................................................4
Gebruikersgemak.................................................................................................................................................4
Kosten...................................................................................................................................................................5
Conclusie..............................................................................................................................................................5
Vergelijkinsgmatrix prostaatcarcinoom, enzalutamide – abiraterone.............................................................6
Bronnenlijst Vergelijkinsgmatrix prostaatcarcinoom, enzalutamide – abiraterone........................................10
Formulariumadvies atriumfibrilleren........................................................................................................... 12
dabigatran – rivaroxaban..................................................................................................................................12
Inleiding.........................................................................................................................................................12
Medicatie bij atriumfibrilleren...........................................................................................................................12
Effectiviteit.........................................................................................................................................................12
Veiligheid............................................................................................................................................................13
Tolerantie...........................................................................................................................................................13
Gebruikersgemak...............................................................................................................................................13
Ervaring..............................................................................................................................................................14
Kosten................................................................................................................................................................14
Conclusie............................................................................................................................................................14
Vergelijkinsgmatrix Atriumfibrilleren, dabigatran – rivaroxaban...................................................................15
Bronnenlijst Vergelijkinsgmatrix dabigatran – rivaroxavan...........................................................................19
Formulariumadvies prostaatcarcinoom
Enzalutamide – abirateron
Inleiding
Het ziekenhuis heeft op verzoek van de formulariumcommissie twee geneesmiddelen,
enzalutamide en abiraterone, geëvalueerd voor de behandeling van prostaatkanker. Deze
evaluatie omvatte een vergelijking op basis van verschillende criteria, waaronder effectiviteit,
veiligheid, tolerantie, gebruikersgemak, ervaring en kosten.
3
